Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;9(1):991-993.
doi: 10.1080/22221751.2020.1760144.

Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient

Affiliations

Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient

Jing Sun et al. Emerg Microbes Infect. 2020 Dec.

Abstract

SARS-CoV-2 caused a major outbreak of severe pneumonia (COVID-19) in humans. Viral RNA was detected in multiple organs in COVID-19 patients. However, infectious SARS-CoV-2 was only isolated from respiratory specimens. Here, infectious SARS-CoV-2 was successfully isolated from urine of a COVID-19 patient. The virus isolated could infect new susceptible cells and was recognized by its' own patient sera. Appropriate precautions should be taken to avoid transmission from urine.

Keywords: COVID-19; SARS-CoV-2; transmission; urine; virus isolation.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Clinical information and isolation of SARS-CoV-2 from a patient’s urine. (A) Clinical events. (B) Cytopathic effect (CPE) were observed in Vero E6 cells that were infected with SARS-CoV-2 isolate after 72 h but not in mock-infected cells. (C) Visualization of viral particles using Transmission Electron Microscopy (TEM). (D) Viral loads in respiratory and urine specimens. OS: oropharyngeal swab. (E) SARS-CoV-2-specific IgG and IgM antibody responses in patient. (F) IFA detection of SARS-CoV-2 infected Vero E6 using patient’s serum. No fluorescence was detected using healthy control serum or in mock-infected cells.

References

    1. Zhu N, Zhang D, Wang W, et al. . A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727–733. doi: 10.1056/NEJMoa2001017 - DOI - PMC - PubMed
    1. Chan JF, Yuan S, Kok KH, et al. . A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb 15;395. - PMC - PubMed
    1. Guan WJ, Ni ZY, Hu Y, et al. . Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708–1720. doi: 10.1056/NEJMoa2002032 - DOI - PMC - PubMed
    1. Pan Y, Zhang D, Yang P, et al. . Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis. 2020 Apr;20(4):411–412. doi: 10.1016/S1473-3099(20)30113-4 - DOI - PMC - PubMed
    1. Zou X, Chen K, Zou J, et al. . Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020 Mar 12. doi: 10.1007/s11684-020-0754-0 - DOI - PMC - PubMed

LinkOut - more resources